





Neonatal Abstinence Syndrome (NAS)

The type and severity of symptoms an infant experiences varies "depending on the type of substance used, the last time it was used, and whether the baby is full-term or premature. Symptoms of withdrawal may begin as early as 24 to 48 hours after birth, or as late as five to 10 days." Among the "most common symptoms" of NAS: "tremors (trembling), irritability (excessive crying), sleep problems, high-pitched crying, tight muscle tone, hyperactive reflexes, seizures, yawning, stuffy nose, and sneezing, poor feeding and suck, vomiting, diarrhea, dehydration, sweating, and fever or unstable temperature."

http://www.stanfordchildrens.org/en/topic/default?id=neonatal-abstinence-syndrome-90-P02387













Similar findings and recommendations

- DHS should "amend its policy for mandatory consultation when a report is received with the allegations related to drug-exposed infants. Currently reports regarding drug-exposed infants are assigned to the intake division for investigation. The DHS policy and planning division is in the process of creating an investigation manual that will update the existing policy to reflect the current process." http://www.dhspagov/cs/groups/webcontent/documents/document/c.236405.pdf
- The local review team expressed "the need for local obstetricians and gynecologists to be educated on
 prevention resources for mothers who abuse drugs during pregnancy." This team also identified that
 "illegal drug use" has been a "reoccurring factor in homes with recent deaths of children."
- An amendment was made to the on-call procedure for the assessment of all newborns. Any active or non-active referrals on call, regarding newborn babies are to have two supervisory reviews before determining final safety. An internal discussion was also held with supervisors regarding the weight of a child's removal based on risk, as well as safety." http://www.dhspagov/cs/groups/webcontent/document/c211844.pdf
- The infant was "known" to the children and youth agency after "a referral was received when the deceased child was born because the mother tested positive for opiates." Indiana and Westmoreland counties had involvement with the family. http://www.dhs.pa.gov/cs/groups/webcontent/documents/report/p.034463.pdf.

© www.C4CJ.org contact@C4CJ.org



"And it's important to know that <u>NAS in and of</u> <u>itself is not fatal</u>. Now the circumstances of NAS certainly put a baby at risk leading to a diagnosis for other adverse outcomes, but babies typically do not die of neonatal abstinence syndrome."

Dr. Michael Warren (April 2015)

https://eliminatechildabusefatalities.sites.usa.gov/event/tennessee-public-meeting/







"Today, children are born all over this country to mothers who have substance abuse problems....These babies are born in hospitals, they are frequently underweight, and they are frequently frail. Much money and effort is devoted to bringing them to health. These children do not meet any definition of child abuse, and probably they should not, but what happens is they are sent home from hospitals every day in this country and it is only a matter of time in so many instances until they return back to the hospital abused, bruised, beaten, and sometimes deceased." – retired PA Congressman James Greenwood April 2002

http://www.gpo.gov/fdsys/pkg/CREC-2002-04-23/pdf/CREC-2002-04-23-pt1-PgH1502







What is a plan of safe care? What entity creates and monitors it?

Federal officials in 2011: CAPTA did not specify whether it is the formal child welfare agency or another entity (e.g., hospital, community-based providers) that is to develop and implement this plan of safe care. ACF emphasized the plan "should address the needs of the child as well as those of the parent(s), as appropriate, and assure that appropriate services are provided to ensure the infant's safety."

https://www.acf.hhs.gov/cwpm/programs/cb/laws_policies/laws/cwpm/policy_dsp.jsp?citID=351







Planning, Coordination, ID Gaps

In order to ensure that efforts to address prenatal opioid use and NAS are systematically and effectively planned and coordinated across the federal government, the Director of Office of National Drug Control Policy (ONDCP) should document the process, including discussions held and information considered, of developing action items on prenatal opioid use and NAS. This may include documenting gaps that were considered in developing action items.

In order to ensure that efforts to address prenatal opioid use and NAS are systematically and effectively planned and coordinated across HHS's agencies, the Secretary of HHS should designate a focal point, such as the Behavioral Health Coordinating Council (BHCC) or another entity, to lead departmental planning and coordination related to prenatal opioid use and NAS, including consideration of gaps in research, programs, and other efforts.

http://www.gao.gov/assets/670/668385.pdf





Protecting Our Infants Act

Because prevention and treatment efforts vary widely from state to state, the new law will help identify evidence-based approaches to care for these babies and their mothers. The law requires the Department of Health and Human Services to conduct a study and develop recommendations for preventing and treating prenatal opioid use disorders and NAS. In addition, the Centers for Disease Control and Prevention will continue to assist states in improving the availability and quality of data collection related to NAS, and encourage public health measures aimed at decreasing its prevalence. Michael Botticelli (November 2015)

www.C4CJ.org contact@C4CJ.org



Protecting Our Infants Act

- The Secretary "shall conduct a study and develop recommendations for preventing and treating prenatal opioid use disorders, including the effects of such disorders on infants."
- A comprehensive assessment of existing research with respect to the prevention, identification, treatment, and long-term outcomes of neonatal abstinence syndrome, including the identification and treatment of pregnant women or women who may become pregnant who use opioids or have opioid use disorders.
- The HHS Secretary "shall conduct a review of planning and coordination related to prenatal opioid use, including neonatal abstinence syndrome, within the agencies of the Department of Health and Human Services." In carrying out this review, the Secretary "shall develop a strategy to address gaps in research and gaps, overlap, and duplication among Federal programs, including those identified in findings made by reports of the Government Accountability office."









HHS Seeks Insight from States by 6/30/16

- Identify state's policies and procedures "to address the needs of infants born with and identified as being affected by illegal substance abuse or withdrawal symptoms resulting from prenatal drug exposure, or a Fetal Alcohol Spectrum Disorder including a requirement that health care providers involved in the delivery or care of such infants notify the child protective services system of the occurrence of such condition of such infants." HHS writes, "We note that such notification should <u>occur in *any* instance in which an infant is</u> <u>demonstrating withdrawal symptoms due to prenatal drug exposure, whether the</u> <u>drugs were obtained legally or illegally</u>."
- 2. Identify "which agency or entity is responsible for developing a plan of safe care, how it is monitored and how follow-up is conducted to ensure the safety of these infants."
- 3. Identify "any technical assistance" that is needed "to improve practice and implementation in these areas, including how to support mothers and families, as well as infants, through a plan of safe care."

http://www.reuters.com/investigates/special-report/baby-opioids/



Commission to Eliminate Child Abuse and Neglect Fatalities

"CAPTA requires assurances from states that policies and procedures are in place regarding the development of a Plan of Safe Care for newborn infants identified as being affected by illegal substance abuse, withdrawal symptoms, or fetal alcohol spectrum disorder. The purpose of this requirement is to ensure that the infants do not leave the hospital without supports in place. The Commission heard from issue experts in the field and spoke with officials at HHS who noted the "lack of teeth" in the CAPTA Plan of Safe Care requirement and its uneven implementation across states. Many state agencies are unfamiliar with this requirement, and no state has designated a single accountable agency or person responsible for its implementation. States' lack of understanding of the policy is reflected in questions submitted to federal officials through the HHS Child Welfare Policy Manual."

Within Our Reach: A National Strategy to Eliminate Child Abuse and Neglect Fatalities, Page 112. Retrieved at https://eliminatechildabusefatalities.sites.usa.gov/files/2016/03/CECANF-final-report.pdf

© www.C4CJ.org contact@C4CJ.org



Commission to Eliminate Child Abuse and Neglect Fatalities

"Amend CAPTA and relevant health policy to clarify the roles and responsibilities at the federal and state level to improve the implementation of CAPTA's Plan of Safe Care. Clarifications should include a requirement for hospitals' full cooperation in implementing Plans of Safe Care and specify accountability measures for both CPS and hospitals in the timely development of Plans of Safe Care and referral of services."



Commission to Eliminate Child Abuse & Neglect Fatalities

Expand annual Child Maltreatment Report to include:

- 1. "The number of births reimbursed by Medicaid in which an infant had a neonatal abstinence syndrome (NAS) diagnosis and the number of NAS-diagnosed infants referred to Part C.
- 2. The number of infants referred under a Plan of Safe Care who were adjudicated dependent in the first year of life and the number who were victims of child abuse or neglect fatalities in the first year of life."





PA Congressional Delegation Acts

- S. 2687 introduced by Senator Casey
- H.R. 4843 introduced by PA Congressman Lou Barletta

The Congressional Budget Office (CBO) released a cost estimate for H.R. 4843 and separately for S. 2687. CBO estimated that "implementing the legislation **would cost less than \$500,000 annually** for additional personnel to carry out the new requirements; such spending would be subject to the availability of appropriated funds." CBO described CAPTA as requiring states that want to be eligible for CAPTA funding to develop "a plan of safe care for any drug dependent infant."

U.S. House Education and Workforce Committee underscores that while H.R. 4843 amends CAPTA, states "should not limit their efforts to address the needs of substance exposed infants and their families to funds available under CAPTA."

 © www.C4CJ.org contact@C4CJ.org



- Federal guidance/direction on best practices for development of Plans of Safe Care
- Enhanced data collection/reporting on number of substance-exposed infants and then those who a Plan of Safe Care was developed
- Enhanced monitoring by HHS of state plans, actions on behalf of these infants and their families







Comprehensive Addiction and Recovery Act

https://www.congress.gov/114/bills/s524/BILLS-114s524enr.pdf

- Substance abuse treatment programs are to make available "therapeutic, comprehensive child care for children" when the child's mother is receiving health and rehabilitative services.
- Creates a competitive pilot grant program to be administered by the Department of Health and Human Services (HHS) to meet the unique needs of pregnant and postpartum women intended, in part, to support family based services within residential and non-residential settings.
- Within the Department of Justice, creates a Comprehensive Opioid Abuse Grant Program to develop or expand treatment alternatives over incarceration, including strategies focused "on parents whose incarceration could result in their children entering the child welfare system."
- The Government Accountability Office (GAO) will study the prevalence of NAS and identify best practices for treating infants diagnosed with NAS.

















Family First Prevention Services Act

H.R. 5456/S.3065

No federal reimbursement for group homes UNLESS the child is in:

- A qualified residential treatment program
- A setting specializing in providing prenatal, post-partum, or parenting supports for youth
- Supervised independent living for youth under age 18

Shortage of foster family homes is not a permitted reason for saying that the child's needs cannot be met in a family type setting.





March 2016: Call for PA Task Force to:

- 1. Prioritize prevention of substance-exposed infants,
- 2. Improve outcomes for pregnant and parenting women striving to recover from addiction; and
- 3. Promote the health, safety and permanency of substanceexposed infants and other young children at-risk of child abuse and neglect or placement in foster care due to parental alcohol and drug use.







NGA/CLASP Two-Generation Strategies

- PA applied for competitive funding (up to \$100K over 2 years) through the National Governors Association (NGA) Center for Best Practices and the Center for Law and Social Policy (CLASP).
- PA's overall proposal framed as a "No wrong door approach to human services." If successful, PA would fund two pilots to develop "a family's needs assessment and checklist" utilized at entry points for human services.
- PA also seeking TA to "ensure appropriate services to infants with neonatal abstinence syndrome and their families."



•An overview of the extent of opioid use by pregnant women and the effects on the infant

Evidence-based recommendations for treatment approaches from leading professional organizations
An in-depth case study, including ideas that can be adopted and adapted by other jurisdictions

•A guide for collaborative planning, including needs and gaps analysis tools for priority setting and action planning https://ncsacw.samhsa.gov/files/Collaborative _Approach_508.pdf



A COLLABORATIVE APPROACH TO THE TREATMENT OF PREGNANT WOMEN WITH OPIOID USE DISORDERS









PRESCRIPTION DRUG MONITORING PROGRA	
PDMP PORTAL (PA PMP AWARXE)	HOME
About	
The Pennsylvania PDMP Portal, PA PMP AWARXE, is a gateway for prescribers, pharmacists, and	their delegates to QUESTIONS & ANSWERS
easily look up their patients' controlled substance prescription history before prescribing or dispensing. This information helps health care providers better identify patients struggling with substance use disorder, so that they can help them get the treatment they need.	
To access PA PMP AWARxE, visit pennsylvania.pmpaware.net.	FOR DISPENSERS
Registration is now open	FOR PRESCRIBERS
All prescribers and pharmacists in the Commonwealth of Pennsylvania, as well as their delegates, c <u>PA PMP AWARxE</u> . The system will be ready for query starting on Aug. 25, 2016.	an now register on FOR PATIENTS
Tips for a successful registration:	PDMP PORTAL
1. Review our <u>Terms and Conditions</u> ^[2] before registering.	
2. Prescribers: Enter your personal DEA number, not your employer's DEA number.	
3 Fnter vour Pennsvlvania Professional License number	
Hea gMo	://www.health.pa.gov/Your-Department-of- lth/Offices%20and%20Bureaus/PaPrescriptionDru nitoringProgram/Pages/PDMP- tal.aspx#.V9k4T2HD9-Q







Prescribing Guidelines for Pennsylvania

USE OF ADDICTION TREATMENT MEDICATIONS IN THE TREATMENT OF PREGNANT PATIENTS WITH OPIOID USE DISORDER

The misuse of opioids has increased significantly over the past decade. Pregnant women are represented in this problem. The 2014 National Survey on Drug Use and Health found that 0.2 individual provider's clinical judgement. All treatment should be determined by the provider and the patient on an individual basis based on needs of the patient.



Revised: January 14, 2016

http://www.health.pa.gov/My %20Health/Diseases%20and% 20Conditions/A-D/Documents/PA%20Guidelin es,%20on%20Obstetrics%20_ Gynogology.pdf

